How AI is applied across API Evangelist and APIs.io. Read my AI disclosure →

NiKang Therapeutics® to Present Preliminary Results of Phase 1/2 Clinical Trial of NKT2152 in Patients with Previously Treated Advanced Clear Cell Renal Cell Carcinoma at ESMO 2024 Congress

calendar_today September 9, 2024 person Elizabeth Aspinall domain nikang-therapeutics

See the press release on Business Wire